Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

The revving up of CARs

Gene Therapy volume 25, page 162 (2018)Cite this article

Subjects

Since the FDA-approval of tisagenlecleucel (KymriahTM, Novartis) in August 2017 to treat acute lymphoblastic leukemia (ALL), ongoing investigations rev’d up and new ones initiated leading up to further approval of axicabtagene ciloleucel (YescartaTM, Kite Pharma) for the treatment of relapsed or refractory large B-cell lymphoma 2 months later.

Albeit major credit for utilizing chimeric antigen receptor (CAR) T cells will remain with Dr. Carl June and his team at Penn, it is important to continue to acknowledge and render due credit to the scientist from St Jude’s who first developed this specific CAR that Dr. June later utilized to cure Emily Whitehead and others. With its FDA approval for select ALL and B-cell lymphoma patients, CAR-T cells will likely be tried across a myriad of medical illnesses—malignant, autoimmune, and infections, leading to significant research funding becoming available [1, 2].

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rosenbaum L. Tragedy, perseverance, and chance—the story of CAR-T therapy. N Engl J Med 2017;377:1313–5.

    Article  Google Scholar 

  2. Kuehn BM. The promise and challenges of CAR-T gene therapy. JAMA 2017;318:2167–9.

    Article  Google Scholar 

  3. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18:676–84.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Internal Medicine, Medical College of Wisconsin (MCW), Milwaukee, WI, USA

    Muhammad Bilal Abid

Authors
  1. Muhammad Bilal Abid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Muhammad Bilal Abid.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abid, M.B. The revving up of CARs. Gene Ther 25, 162 (2018). https://doi.org/10.1038/s41434-018-0015-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41434-018-0015-x

This article is cited by

Search

Advanced search

Quick links